- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | CAMP4 receives UK authorization for SYNGAP1 trial of CMP-002 | 3 | Investing.com | ||
| 10.09. | CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder | 302 | GlobeNewswire (Europe) | Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4's recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina... ► Artikel lesen | |
| 09.09. | Camp4 Therapeutics auf Cantor-Konferenz: Erste SYNGAP1-Studie wird vorangetrieben | 2 | Investing.com Deutsch | ||
| 08.09. | CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 | 3 | GlobeNewswire (USA) | ||
| 13.08. | Camp4 Therapeutics GAAP EPS of -$0.58 misses by $0.37 | 1 | Seeking Alpha | ||
| CAMP4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.08. | Camp4 Therapeutics Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | CAMP4 closes $50.1 million second tranche of private placement | 1 | Investing.com | ||
| 04.08. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 04.08. | CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement | 183 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4" or "the Company") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory... ► Artikel lesen | |
| 27.07. | CAMP4 receives Australian clearance for SYNGAP1 therapy trial | 3 | Investing.com | ||
| 27.07. | CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder | 372 | GlobeNewswire (Europe) | Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through... ► Artikel lesen | |
| 27.07. | Camp4 Therapeutics Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 17.07. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 19.06. | CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 16.06. | Potenzial von CMP-002: JPMorgan stuft CAMP4 Therapeutics auf "Overweight" hoch | 10 | Investing.com Deutsch | ||
| 16.06. | JPMorgan upgrades CAMP4 Therapeutics stock rating on CMP-002 potential | 2 | Investing.com | ||
| 12.06. | Camp4 Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Chardan initiates CAMP4 Therapeutics stock with buy rating | 2 | Investing.com | ||
| 21.05. | CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,664 | +1,96 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| CARDIFF ONCOLOGY | 1,120 | -6,43 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 1,170 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 17,550 | +2,18 % | Denali Therapeutics: Markteinführung von Avlayah gewinnt an Fahrt | ||
| ABCELLERA BIOLOGICS | 10,920 | 0,00 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 24,770 | -0,56 % | Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ | Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity... ► Artikel lesen | |
| AC IMMUNE | 2,300 | -0,22 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,112 | -4,39 % | Coherus auf Morgan Stanley Konferenz: Onkologie-Strategie gewinnt an Dynamik | ||
| CYTOMX THERAPEUTICS | 2,420 | +0,88 % | CytomX auf Morgan Stanley Konferenz: Strategie für fortgeschrittenes Kolorektalkarzinom im Fokus | ||
| CYBIN | 11,120 | +3,35 % | Helus Pharma auf Morgan Stanley Konferenz: Strategie zielt auf breiteren Depressionsmarkt | ||
| AGENUS | 6,400 | -6,57 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,040 | +0,06 % | Arcturus to present Phase 2 data for OTC deficiency treatment |
CAMP4 THERAPEUTICS CORP gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMP4 THERAPEUTICS CORP finden Sie auf Wallstreet Online.